Diet and risk of glioma: combined analysis of 3 large prospective studies in the UK and USA

Ai Seon Kuan,Amy Berrington De González,Angela Balkwill,Cari M Kitahara,Gillian K. Reeves,Jane Green,Kathryn Bradbury,Linda M Liao,Neal D Freedman,Sarah Floud,Sian Sweetland,The Million Women Study, the NIH-AARP study, and the PLCO study,Tim Key,Valerie Beral

Safety and efficacy of depatuxizumab mafodotin + temozolomide in patients with EGFR-amplified, recurrent glioblastoma: results from an international phase I multicenter trial

Andrew B Lassman,Andrew M Scott,David A Reardon,David Maag,Earle Bain,Erica Gomez,Hao Xiong,Helen Wheeler,Ho-Jin Lee,Hui K Gan,John Simes,Kyle D Holen,Kyriakos P Papadopoulos,Lisa Roberts-Rapp,Louis B Nabors,Marta Penas-Prado,Martin J van den Bent,Nicholas Butowski,Peter J Ansell,Priya Kumthekar,Ryan Merrell,Tobias Walbert,Tom Mikkelsen,Zarnie Lwin

Disparities along the glioblastoma clinical trials landscape

Ethan B Ludmir,Jacob J Mandel,John F de Groot,Mary Frances McAleer

Durable response to mTOR inhibition in a patient with relapsing papillary tumor of the pineal region

Anna B？ng-Rudenstam,Elisabet Englund,Mattias Belting,Torsten Pietsch

Liquid biopsy in central nervous system metastases: a RANO review and proposals for clinical applications

Adrienne Boire,Dieta Brandsma,Emilie Le Rhun,Eudocia Q Lee,Jeffrey Raizer,Larry Junck,Manmeet Ahluwalia,Martin J Van den Bent,Michael A Vogelbaum,Michael Glantz,Michael Weller,Morris D Groves,Nancy Lin,Patrick Y Wen,Priscilla K Brastianos,Riccardo Soffietti,Roberta Rudà,Susan Chang

Malignant primary brain and other central nervous system tumors diagnosed in Canada from 2009 to 2013

CBTR founding affiliates,Emily V Walker,Faith G Davis

Inflammation and vascular permeability correlate with growth in sporadic vestibular schwannoma

Alan Jackson,Andrea Wadeson,Andrew T King,Charlotte Hammerbeck-Ward,D Gareth Evans,Daniel Lewis,David J Coope,Dominic Mosses,Emma Stapleton,Erjon Agushi,Federico Roncaroli,Helen Mayers,Ka-loh Li,Omar Pathmanaban,Rainer Hinz,Ricky Williams,Ross Atkinson,Scott A Rutherford,Sharon Hulme,Simon K L Lloyd,Simon R Freeman,Xiaoping Zhu

Intratumor DNA methylation heterogeneity in glioblastoma: implications for DNA methylation-based classification

Anna Wenger,Asgeir Store Jakola,Helena Carén,Sandra Ferreyra Vega,Teresia Kling,Thomas Olsson Bontell

Prognostic relevance of genetic alterations in diffuse lower-grade gliomas

Atsushi Natsume,Fumiharu Ohka,Hideo Nakamura,Hiromichi Suzuki,Hironori Yajima,Ichiro Ito,Ichiro Takeuchi,Kazuya Motomura,Keisuke Kataoka,Keitaro Matsuo,Kosuke Aoki,Masahiro Mizoguchi,Masashi Sanada,Naoya Morita,Reiko Watanabe,Satoru Miyano,Satoshi Shiina,Seishi Ogawa,Takashi Yamamoto,Tatsuya Abe,Teppei Shimamura,Tetsuichi Yoshizato,Toshihiko Wakabayashi,Yasunobu Nagata,Yasutomo Momii,Yoshihiro Muragaki

Activation of WEE1 confers resistance to PI3K inhibition in glioblastoma

Dimpy Koul,Feng Gao,Luyuan Li,Shaofang Wu,Shuzhen Wang,Siyuan Zheng,W K Alfred Yung

MerTK as a therapeutic target in glioblastoma

Allison N Schorzman,C Ryan Miller,David M Irvin,Erik P Sulman,H Shelton Earp,Jing Wu,Lauren N Frady,Mark R Gilbert,Matthew G Ewend,Ryan E Bash,Stephanie M Cohen,Stephen V Frye,William C Zamboni,Xiaodong Wang,Yu-Ting Su

The impact of surgery in molecularly defined low-grade glioma: an integrated clinical, radiological, and molecular analysis

Arnaud J P E Vincent,Clemens M F Dirven,Geert-Jan Rutten,Hendrikus J Dubbink,Jeroen B Verheul,Johan M Kros,Maarten M J Wijnenga,Marion Smits,Martin J van den Bent,Peggy N Atmodimedjo,Pim J French,Renske Gahrmann,Ruth Fleischeuer,Winand N M Dinjens

The siren song of bevacizumab: swan song or clarion call?

David Schiff,Patrick Y Wen

Forthcoming Meetings

Comment on “Response assessment in medulloblastoma and leptomeningeal seeding tumors: recommendations from the Response Assessment in Pediatric Neuro-Oncology Committee”

Julie H Harreld

Longitudinal assessment of late-onset neurologic conditions in survivors of childhood central nervous system tumors: a Childhood Cancer Survivor Study report

Allison King,Charles A Sklar,Elizabeth M Wells,Gregory T Armstrong,Joseph P Neglia,Kevin C Oeffinger,Kevin R Krull,Kimberly Whelan,Kristy Seidel,Leslie L Robison,Lisa Diller,Marilyn Stovall,Nicole J Ullrich,Roger J Packer,Wendy Leisenring

EAPH-11. INTRAVENTRICULAR THERAPY ALTERNATING ETOPOSIDE, AQUEOUS CYTARABINE AND TOPOTECAN IS FEASIBLE AND SAFE: EXPERIENCE IN 26 PEDIATRIC PATIENTS WITH MALIGNANT BRAIN TUMORS

EAPH-07. CHILDREN’S BRAIN TUMOUR DRUG DELIVERY CONSORTIUM

Ritanserin, a novel agent targeting the mesenchymal subtype of glioblastomas

Alessandra Audia,Krishna P Bhat

Pediatric low-grade gliomas: a brave new world

Jonathan L Finlay,Joshua B Rubin

EAPH-12. CELASTROL INDUCED DEGRADATION OF FANCD2 SENSITIZES PEDIATRIC HIGH-GRADE GLIOMA TO THE DNA-CROSSLINKING AGENT CARBOPLATIN

EAPH-10. SUCCESSFUL TREATMENT OF A SECONDARY PEDIATRIC HIGH GRADE GLIOMA WITH A NOVEL BEND4-NTRK2 FUSION WITH ENTRECTINIB, A TRK INHIBITOR

Pediatric low-grade gliomas: next biologically driven steps

Angela J Waanders,Antoinette Y N Schouten van Meeteren,Cynthia Hawkins,Daniel C Bowers,Darren Hargrave,David Ellison,David T W Jones,David Walker,Eric Bouffet,Giorgio Perilongo,Jason Fangusaro,Karen Wright,Katherine Warren,Mark W Kieran,Maryam Fouladi,Maura Massimino,Michael J Fisher,Miriam Bornhorst,Nada Jabado,Nicholas Foreman,Olaf Witt,Pratiti Bandopadhayay,Roger J Packer,Sabine Mueller,Sanda Alexandrescu,Stefan M Pfister,Uri Tabori,William Weiss,Yuan Zhu

microRNA-7 upregulates death receptor 5 and primes resistant brain tumors to caspase-mediated apoptosis

Benjamin Purow,Deepak Bhere,Hiroaki Wakimoto,Jeremy Debatisse,Kaoru Tamura,Khalid Shah,Sung Hugh Choi

Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma

Abdul-Kareem Ahmed,Agnieszka Bronisz,Brian W Guzik,Carmela Passaro,David A Reardon,E Antonio Chiocca,Estuardo Aguilar-Cordova,Franz Ricklefs,Gordon J Freeman,Hiroshi Nakashima,Johanna K Kaufmann,Kazue Kasai,Laura K Aguilar,Maria-Carmela Speranza,Michal O Nowicki,Patrick Y Wen,Prisca Obi,Ralph Weissleder,Sarah R Klein,Sean E Lawler,Xandra Breakefield

Corrigendum

Diffusion-weighted MRI may support the identification of non-enhancing IDH wildtype astrocytoma

Risk factors for developing post-operative seizures following meningioma resection

A human iPS cell-based model of medulloblastoma demonstrates co-operativity between SHH signalling and mutation in an epigenetic modifier

Understanding missed opportunities for more timely diagnosis of brain cancer – what can we learn from the BRACED qualitative interview study with adult glioma patients?

Neuro-oncology family caregivers’ view on keeping track of care issues using eHealth systems: it’s a question of time

EAPH-16. DISCOVERY OF CT-179: A SMALL MOLECULE INHIBITOR OF THE OLIG2 TRANSCRIPTION FACTOR WITH POTENT ANTI-TUMOR IN PEDIATRIC BRAIN CANCER

EMBR-01. MOLECULAR AND CLINICAL HETEROGENEITY IN HISTOLOGICALLY-DIAGNOSED CNS-PNET PATIENTS PROSPECTIVELY TREATED AS A SINGLE ENTITY: A REPORT FROM THE CHILDREN’S ONCOLOGY GROUP ACNS0332 TRIAL

EAPH-15. COMBINATION THERAPY WITH VINCRISTINE, IRINOTECAN, AND TEMOZOLOMIDE IN CENTRAL NERVOUS SYSTEM MALIGNANCIES

EAPH-14. MOLECULAR BIOLOGY AND PHASE I STUDY OF GM-CSF AND INTRATHECAL TRASTUZUMAB IN CHILDREN WITH RECURRENT POSTERIOR FOSSA EPENDYMOMA

Irradiation of glioblastoma cells can promote enhanced motility and invasiveness, both in vitro and in vivo through activation of MRCK

Investigating the role of TAM family receptors in Merlin deficient tumours

A spectroscopic serum based blood test for brain tumours: Optimisation for high-throughput sampling and the health economic impacts

EMBR-05. TUMORS OF THE PINEAL REGION CAN BE CLASSIFIED INTO DISTINCT SUBGROUPS BASED ON MOLECULAR CHARACTERISTICS CORRELATING WITH CLINICAL PARAMETERS AND GENETIC ALTERATIONS

EMBR-02. RECURRENT HOMOZYGOUS DELETION OF DROSHA AND MICRODUPLICATION OF PDE4DIP CONTAINING THE ANCESTRAL DUF1220 DOMAIN IN PINEOBLASTOMA

EMBR-04. WHAT THE FOX SAY? A MOLECULAR ANALYSIS OF FOXR2 IN PEDIATRIC BRAIN TUMORS

EMBR-08. CHOROID PLEXUS TUMORS IN 2018: THE CPT-SIOP EXPERIENCE AND LONG-TERM OUTCOME

EMBR-16. SURVIVAL OF INFANTS AND YOUNG CHILDREN WITH MALIGNANT BRAIN TUMORS TREATED WITH INTENSIVE INDUCTION AND MYELOABLATIVE CHEMOTHERAPY AND AUTOLOGOUS HEMATOPOIETIC PROGENITOR CELL RESCUE (AUHCR) WITH OR WITHOUT IRRADIATION (XRT) POST-AUHCR

EMBR-15. DIAGNOSTIC RE-EVALUATION AND POOLED CLINICAL DATA ANALYSIS OF PATIENTS WITH PREVIOUS DIAGNOSIS OF CNS-PNET

The impact of visual impairment on Health-Related Quality of Life (HRQoL) scores in brain tumour patients

EMBR-13. FAVORABLE OUTCOMES IN CHILDREN WITH PINEOBLASTOMA TREATED WITH RISK-ADAPTED CRANIOSPINAL IRRADIATION AND CHEMOTHERAPY: RESULTS AND MOLECULAR ANALYSIS FROM THE SJYC07 AND SJMB03 TRIALS

Eradication of Glioblastoma Multiforme stem-cells with Immunotargeted-molecular-robotic-NANOSURGERY (ITMRN)

Prof John Giannios

A retrospective review of clinical outcome and hippocampus dosimetry in patients treated with stereotactic radiosurgery for brain metastases in South Wales

Phytochemicals - an alternative therapy for glioblastoma?

Choroid plexus tumors in infants and young children - Lessons learnt from an institutional review